In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies

NCT01430390 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

19

Enrollment

OTHER

Sponsor class

Conditions

Acute Lymphocytic Leukemia
Lymphoma

Interventions

BIOLOGICAL: Biological/Genetically Modified T cells
DRUG: Cyclophosphamide-based chemotherapy

Sponsor

Memorial Sloan Kettering Cancer Center